Point72 Asset Management L.P. Lowers Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Point72 Asset Management L.P. cut its holdings in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 58.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 215,160 shares of the company's stock after selling 301,774 shares during the period. Point72 Asset Management L.P. owned approximately 0.35% of Health Catalyst worth $1,521,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. SG Americas Securities LLC boosted its stake in Health Catalyst by 21.7% during the 4th quarter. SG Americas Securities LLC now owns 27,382 shares of the company's stock valued at $194,000 after purchasing an additional 4,874 shares during the last quarter. Inspire Investing LLC boosted its stake in Health Catalyst by 14.2% during the 4th quarter. Inspire Investing LLC now owns 56,379 shares of the company's stock valued at $399,000 after purchasing an additional 7,019 shares during the last quarter. Dynamic Advisor Solutions LLC acquired a new position in Health Catalyst during the 4th quarter valued at about $180,000. Stoneridge Investment Partners LLC purchased a new position in shares of Health Catalyst in the 4th quarter worth approximately $77,000. Finally, Legato Capital Management LLC boosted its stake in shares of Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock worth $622,000 after buying an additional 3,171 shares during the last quarter. 85.00% of the stock is owned by institutional investors.

Health Catalyst Price Performance

Shares of Health Catalyst stock traded up $0.09 during trading on Tuesday, hitting $3.74. The stock had a trading volume of 69,745 shares, compared to its average volume of 597,097. The firm has a market cap of $259.96 million, a price-to-earnings ratio of -2.77 and a beta of 1.56. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 12 month low of $3.54 and a 12 month high of $9.24. The business's 50-day moving average is $4.06 and its 200 day moving average is $5.60.

Analysts Set New Price Targets

HCAT has been the topic of a number of research analyst reports. Citigroup cut their target price on Health Catalyst from $7.00 to $6.50 and set a "buy" rating on the stock in a research note on Friday, April 25th. Piper Sandler cut their target price on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 11th. KeyCorp cut their target price on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Canaccord Genuity Group cut their target price on Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Evercore ISI lowered Health Catalyst from an "outperform" rating to an "inline" rating in a research note on Wednesday, April 9th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Health Catalyst presently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Insider Activity at Health Catalyst

In other news, General Counsel Benjamin Landry sold 13,827 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the transaction, the general counsel now directly owns 160,437 shares of the company's stock, valued at approximately $729,988.35. This trade represents a 7.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the transaction, the chief operating officer now directly owns 216,250 shares in the company, valued at $977,450. This trade represents a 7.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,147 shares of company stock valued at $182,284 over the last 90 days. 2.50% of the stock is owned by insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.